🩸💥 Many have asked: “Where did the EAU #thromboprophylaxis guideline go?” Don’t worry. Check out cluevte.org 🚀 ✅ Not just #urology, also #gynecology & abd #surgery ✅ Procedure-specific VTE & bleeding risks ✅ Free interactive tool + static infographics #EBM

Presented at #ESMO25: In muscle-invasive bladder cancer, ctDNA-guided atezolizumab led to longer disease-free survival (9.9 vs. 4.8 months), as well as to longer overall survival (32.8 vs. 21.1 months), than placebo among ctDNA-positive patients. Full IMvigor011 phase 3 trial

🎶 Wondering how to tackle variant histologies in bladder cancer? Think of them as music genres—same stage, different openers (neoadj.) and headliners (1st line tx). 🎤 From micropapillary to plasmacytoid—each has a style & strategy. 🎧 Watch here ⬇️ Uromigos David H Aggen, MD PhD

This is a fantastic infographic on the PSA test for prostate cancer screening (and why it's not recommended in the general population)

🧬 Germline testing in #ProstateCancer shows 💡 ✅ 93% of pts w/ +results follow clinical advice 😌 >90% report no added anxiety ⚠️ But... VUS confusion = mismatched care plans 🧠 Better communication needed! 🔗doi.org/10.1038/s41391…

Norris. Verstappen. Piastri. 🍿 Here's how we could see a World Champion crowned in Abu Dhabi 🏆👇 #F1 #AbuDhabiGP

I spy Mike ODonnell and Mohamad Abou Chakra front and center there. Better quality TURBT = more effective intravesical therapy!

Strong data from Frederick L. Locke lab et al supporting what was up to now only intuited; namely, that non-engineered endogenous T cells contribute to CD19 CAR T efficacy. Loss of MHC-I was identified as a key resistance mechanism. Should we look at this more systematically in the

Great collab with University of Illinois Chicago male infertility team! New review: “Male reproductive and sexual health outcomes following intravesical therapy for NMIBC” Fertility & sexual function = key quality-of-life issues for bladder cancer patients. pubmed.ncbi.nlm.nih.gov/41175262/ sam ohlander

This month in actasurologicas Sex-specific bladder cancer incidence trends and generational effects ... sciencedirect.com/science/articl…

GU Research Digest for the week of November 29 - December 5: a selection of publications about GU cancers in high-impact journals. Search the PMIDs on pubmed.ncbi.nlm.nih.gov to read!

The editors announce the launch of NEJM Clinician (follow 👉 NEJM Clinician), a new digital publication for clinicians, by clinicians. Read the editorial: nej.md/4roG5vK

Baseline urinary tumor DNA, minimal residual disease, and genomic disease burden in relation to clinical response to TAR-200 in the phase 2b SunRISe-1 trial. Presentation by Girish Kulkarni Univ of Toronto Urology. #SUO25 written coverage by Rashid K. Sayyid UA Urology > bit.ly/48HuYp6 Society of Urologic Oncology

T cell engagers have demonstrated efficacy in 'cold' tumors, but where do the T cells come from? and how can we improve response? With Julien Sage and Chris Garcia, we show that TCEs recruit new T cell clones to the tumor, ala PD-1 blockade, and can be improved with cytokine

The 2025 Amer. Urol. Assn. #Hematuria guidelines: Overview of recommendations and risk stratification. Presentation by yair lotan UT Southwestern Medical Center. #SUO25 written coverage by Zach Klaassen Georgia Cancer Center > bit.ly/4iO6Fue Society of Urologic Oncology

Some thoughts on CREST, POTOMAC, AND ALBAN. These trials all evaluated BCG Naive NMIBC, randomizing BCG vs BCG + IO. I have a few thoughts on how we should interpret 2 meekly positive trials (CREST/POTOMAC) in the face of one negative trial (ALBAN)

Always used hemostatic agents for PNx, then used for 50% of cases during the trial, now will only use very selectively.....lots of gratitude to the team and patients who made this happen auajournals.org/doi/10.1097/JU…

🇫🇷 GETUG-AFU 30 phase 2 randomized trial : - For patients with pathological high-risk MIBC, adjuvant RT is Safe and Feasible - All patients received the full prescribed dose without early termination or discontinuation. - Low rates of Gi / Gu acute toxicity were observed!

🔔Urologic Oncology: January issue! 👉Thoracic epidural anesthesia, rectus sheath block, and surgeon infiltration (with liposomal or standard bupivacaine) achieve similar pain control and opioid use for open cystectomy Click here to read the article ▶️ bit.ly/48VLKB4

By the way, if you want to learn directly from leaders like Mohit Khera and Rachel Rubin, this is your chance. We’ll be diving deep into the science, the evidence, and the clinical realities of testosterone therapy. Join us in Orlando on January 16–17, 2026, or attend via